r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

MS

Maged Shenouda

Insider · Chief Financial Officer · RLMD

Maged Shenouda files insider transactions with the SEC as a chief financial officer of Relmada Therapeutics. We hold 2 disclosed purchases and sales filed since 16 December 2015, 2 of them in the last 90 days.

  • Files for 3 companiesRLMD, AZRX, PRGB
  • Disclosed buys and sells2 in all, 2 in the last 90 days
  • Last disclosure11 September 2026

Positions held

3 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 14 December 2015 — 10 September 2026Chief Financial Officer · Relmada Therapeutics 68 Form 4 lines · source: SEC Form 4
  • Filed 3 February 2017 — 28 December 2018Chief Financial Officer · AzurRx BioPharma 5 Form 4 lines · source: SEC Form 4
  • Filed 18 December 2015 — 18 December 2015Director · Protea Biosciences Group 2 Form 4 lines · source: SEC Form 4

Every transaction

75 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
75 of 75 shown
10 Sep 202611 Sep 2026SEC Form 41 dbought on the open marketRelmada Therapeutics79,800 sharesup +11.1%up +0.0%
9 Sep 202611 Sep 2026SEC Form 42 dbought on the open marketRelmada Therapeutics120,200 sharesup +10.5%up +0.0%
15 Dec 202516 Dec 2025SEC Form 41 dbought on the open marketRelmada Therapeutics11,665 sharesup +3.7%up +0.4%
12 Dec 202516 Dec 2025SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative828,000 sharesup +11.3%up +0.4%
5 Nov 20256 Nov 2025SEC Form 41 dbought on the open marketRelmada Therapeutics500,000 sharesup +80.1%up +73.2%
26 Jun 202530 Jun 2025SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative600,000 sharesup +571.6%up +653.3%
20 May 202520 May 2025SEC Form 40 dbought on the open marketRelmada Therapeutics60,000 sharesup +657.1%up +657.1%
19 May 202520 May 2025SEC Form 41 dbought on the open marketRelmada Therapeutics90,000 sharesup +788.0%up +657.1%
16 May 202520 May 2025SEC Form 44 dbought on the open marketRelmada Therapeutics50,000 sharesup +880.5%up +657.1%
11 Sep 202411 Sep 2024SEC Form 40 dbought on the open marketRelmada Therapeutics24,120 sharesup +49.7%up +49.7%
10 Sep 202411 Sep 2024SEC Form 41 dbought on the open marketRelmada Therapeutics21,118 sharesup +60.9%up +49.7%
9 Sep 202411 Sep 2024SEC Form 42 dbought on the open marketRelmada Therapeutics8,194 sharesup +62.0%up +49.7%
24 May 202429 May 2024SEC Form 45 dwas grantednot a tradeRelmada Therapeuticsderivative54,624 sharesup +48.2%up +54.3%
24 May 202429 May 2024SEC Form 45 dacquired or disposed of, othernot a tradeRelmada Therapeuticsderivative54,624 sharesup +48.2%up +54.3%
31 Jan 202431 Jan 2024SEC Form 40 dbought on the open marketRelmada Therapeutics6,875 sharesup +15.0%up +15.0%
30 Jan 202431 Jan 2024SEC Form 41 dbought on the open marketRelmada Therapeutics15,000 sharesup +13.6%up +15.0%
29 Jan 202431 Jan 2024SEC Form 42 dbought on the open marketRelmada Therapeutics10,800 sharesup +21.5%up +15.0%
15 Dec 202319 Dec 2023SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative82,090 sharesup +82.3%up +82.3%
25 May 202330 May 2023SEC Form 45 dwas grantednot a tradeRelmada Therapeuticsderivative317,643 sharesup +59.2%up +52.2%
16 Dec 202220 Dec 2022SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative194,917 sharesup +34.1%up +41.2%
16 Dec 202220 Dec 2022SEC Form 44 dacquired or disposed of, othernot a tradeRelmada Therapeuticsderivative200,000 sharesup +34.1%up +41.2%
25 May 202226 May 2022SEC Form 41 dwas grantednot a tradeRelmada Therapeuticsderivative295,211 sharesdown −76.5%down −75.8%
25 May 202226 May 2022SEC Form 41 dwas grantednot a tradeRelmada Therapeuticsderivative200,000 sharesdown −76.5%down −75.8%
17 Dec 202121 Dec 2021SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative227,518 sharesdown −76.2%down −78.4%
10 Mar 202110 Mar 2021SEC Form 40 dsold on the open marketRelmada Therapeutics2,373 sharesdown −87.0%down −87.0%
9 Mar 202110 Mar 2021SEC Form 41 dsold on the open marketRelmada Therapeutics5,727 sharesdown −87.0%down −87.0%
9 Mar 202110 Mar 2021SEC Form 41 dsold on the open marketRelmada Therapeutics1,800 sharesdown −87.0%down −87.0%
8 Mar 202110 Mar 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeuticsderivative10,000 sharesdown −86.9%down −87.0%
8 Mar 202110 Mar 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeutics10,000 sharesdown −86.9%down −87.0%
8 Mar 202110 Mar 2021SEC Form 42 dsold on the open marketRelmada Therapeutics100 sharesdown −86.9%down −87.0%
24 Feb 202126 Feb 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeutics3,000 sharesdown −86.9%down −86.4%
24 Feb 202126 Feb 2021SEC Form 42 dsold on the open marketRelmada Therapeutics1,600 sharesdown −86.9%down −86.4%
24 Feb 202126 Feb 2021SEC Form 42 dsold on the open marketRelmada Therapeutics1,400 sharesdown −86.9%down −86.4%
24 Feb 202126 Feb 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeuticsderivative3,000 sharesdown −86.9%down −86.4%
11 Feb 202116 Feb 2021SEC Form 45 dexercised options overnot a tradeRelmada Therapeuticsderivative1,428 sharesdown −87.5%down −88.2%
11 Feb 202116 Feb 2021SEC Form 45 dexercised options overnot a tradeRelmada Therapeutics1,428 sharesdown −87.5%down −88.2%
11 Feb 202116 Feb 2021SEC Form 45 dsold on the open marketRelmada Therapeutics1,428 sharesdown −87.5%down −88.2%
10 Feb 202110 Feb 2021SEC Form 40 dsold on the open marketRelmada Therapeutics2,410 sharesdown −87.1%down −87.1%
9 Feb 202110 Feb 2021SEC Form 41 dsold on the open marketRelmada Therapeutics5,359 sharesdown −87.1%down −87.1%
8 Feb 202110 Feb 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeuticsderivative11,372 sharesdown −87.1%down −87.1%
8 Feb 202110 Feb 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeutics11,372 sharesdown −87.1%down −87.1%
8 Feb 202110 Feb 2021SEC Form 42 dsold on the open marketRelmada Therapeutics3,603 sharesdown −87.1%down −87.1%
3 Feb 20214 Feb 2021SEC Form 41 dsold on the open marketRelmada Therapeutics100 sharesdown −86.9%down −86.6%
2 Feb 20214 Feb 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeutics3,200 sharesdown −87.1%down −86.6%
2 Feb 20214 Feb 2021SEC Form 42 dsold on the open marketRelmada Therapeutics3,100 sharesdown −87.1%down −86.6%
2 Feb 20214 Feb 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeuticsderivative3,200 sharesdown −87.1%down −86.6%
27 Jan 202129 Jan 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeuticsderivative3,000 sharesdown −85.7%down −86.2%
27 Jan 202129 Jan 2021SEC Form 42 dexercised options overnot a tradeRelmada Therapeutics3,000 sharesdown −85.7%down −86.2%
27 Jan 202129 Jan 2021SEC Form 42 dsold on the open marketRelmada Therapeutics1,800 sharesdown −85.7%down −86.2%
27 Jan 202129 Jan 2021SEC Form 42 dsold on the open marketRelmada Therapeutics1,200 sharesdown −85.7%down −86.2%
26 Jan 202126 Jan 2021SEC Form 40 dsold on the open marketRelmada Therapeutics607 sharesdown −86.9%down −86.9%
25 Jan 202126 Jan 2021SEC Form 41 dsold on the open marketRelmada Therapeutics1,280 sharesdown −87.3%down −86.9%
22 Jan 202127 Jan 2021SEC Form 45 dexercised options overnot a tradeRelmada Therapeutics4,000 sharesdown −87.3%down −85.7%
22 Jan 202126 Jan 2021SEC Form 44 dexercised options overnot a tradeRelmada Therapeutics4,000 sharesdown −87.3%down −86.9%
22 Jan 202126 Jan 2021SEC Form 44 dsold on the open marketRelmada Therapeutics1,704 sharesdown −87.3%down −86.9%
22 Jan 202126 Jan 2021SEC Form 44 dsold on the open marketRelmada Therapeutics409 sharesdown −87.3%down −86.9%
22 Jan 202126 Jan 2021SEC Form 44 dexercised options overnot a tradeRelmada Therapeuticsderivative4,000 sharesdown −87.3%down −86.9%
7 Jan 202111 Jan 2021SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative127,500 sharesdown −87.2%down −87.1%
7 Jan 202111 Jan 2021SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative127,500 sharesdown −87.2%down −87.1%
19 Dec 201923 Dec 2019SEC Form 44 dwas grantednot a tradeRelmada Therapeuticsderivative120,000 sharesdown −89.6%down −89.3%
21 Oct 201921 Oct 2019SEC Form 40 dbought on the open marketRelmada Therapeutics978 sharesdown −84.9%down −84.9%
29 Jul 201930 Jul 2019SEC Form 41 dwas grantednot a tradeRelmada Therapeuticsderivative500,000 sharesdown −48.6%down −46.9%
28 Dec 20182 Jan 2019SEC Form 45 dbought on the open marketAzurRx BioPharma20,000 sharesdown −100.0%down −100.0%
20 Dec 201820 Dec 2018SEC Form 40 dwas grantednot a tradeRelmada Therapeuticsderivative450,000 sharesdown −1.7%down −1.7%
12 Jul 201816 Jul 2018SEC Form 44 dwas grantednot a tradeAzurRx BioPharmaderivative100,000 sharesdown −100.0%down −100.0%
20 Oct 201723 Oct 2017SEC Form 43 dwas grantednot a tradeRelmada Therapeuticsderivative425,000 sharesup +39.5%up +32.9%
19 Oct 201723 Oct 2017SEC Form 44 dwas grantednot a tradeAzurRx BioPharma22,500 sharesdown −100.0%down −100.0%
25 Sep 201727 Sep 2017SEC Form 42 dwas grantednot a tradeAzurRx BioPharmaderivative100,000 sharesdown −100.0%down −100.0%
3 Feb 20177 Feb 2017SEC Form 44 dwas grantednot a tradeAzurRx BioPharmaderivative30,000 sharesdown −100.0%down −100.0%
18 Dec 20157 Jan 2016SEC Form 420 dwas grantednot a tradeProtea Biosciences Group100,000 shares——
18 Dec 20157 Jan 2016SEC Form 420 dwas grantednot a tradeProtea Biosciences Groupderivative66,667 shares——
15 Dec 201517 Dec 2015SEC Form 42 dbought on the open marketRelmada Therapeutics2,000 sharesdown −64.7%down −65.2%
15 Dec 201517 Dec 2015SEC Form 42 dbought on the open marketRelmada Therapeutics241 sharesdown −64.7%down −65.2%
15 Dec 201517 Dec 2015SEC Form 42 dbought on the open marketRelmada Therapeutics759 sharesdown −64.7%down −65.2%
14 Dec 201516 Dec 2015SEC Form 42 dbought on the open marketRelmada Therapeutics2,000 sharesdown −62.3%down −69.5%

Both percentages are the stock’s move, not Maged Shenouda’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 73 of the 75 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.